Bloomington, Minnesota Clinical Trials

A listing of Bloomington, Minnesota clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 53 clinical trials
Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)

Phase 1: The investigators will conduct a prospective study to quantify the association between axillary web syndrome (AWS) and metastatic disease and chronic morbidities such as lymphedema, shoulder dysfunction, and pain comparing women (i) with AWS and (ii) without AWS in two cohorts of women. (n=200) Phase 2: This is …

sentinel lymph node biopsy
cancer treatment
prophylactic
sentinel node
lumpectomy
University of Minnesota Masonic Cancer Center
 (9.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

This is a non-randomized, open-label, multi-site, single-dose, Phase 3 study in approximately 35 adults and pediatric subjects 2 and 50 years of age with sickle cell disease (SCD). The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) with LentiGlobin BB305 Drug Product for SCD.

priapism
analgesia
karnofsky performance status
pediatric
gene therapy
University of Minnesota
 (9.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia (ATLAS-NEO)

This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory …

University of Minnesota Site Number : 8400016
 (9.1 away) Contact site
  • 0 views
  • 24 May, 2024
  • +53 other locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the …

HIV Infection
non-squamous non-small cell lung cancer
immunohistochemistry
kaposi sarcoma
stage ii lung squamous cell carcinoma ajcc v7
Fairview Southdale Hospital
 (2.8 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +358 other locations
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

fludarabine
monoclonal antibodies
leukemia
chronic lymphocytic leukemia
monoclonal protein
University of Minnesota Masonic Cancer Center
 (9.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +2 other locations
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy …

HIV Infection
ct scan
adenocarcinoma of esophagus
positron emission tomography
metastatic gastric cancer
Fairview Southdale Hospital
 (2.8 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +254 other locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

folic acid
proto-oncogene tyrosine-protein kinase ros
adjuvant
liquid biopsy
pembrolizumab
Minnesota Oncology Hematology, P.A.
 (2.8 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +27 other locations
The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Vaccination

Hypothesis: Infections other than HIV can cause LN inflammation and collagen damage to the fibroblastic reticular cell network (FRCn), which will lead to CD4 T cell depletion and impaired vaccine responses. This protocol will study yellow fever vaccine (YFV) in two cohorts of people, one from Uganda and the other …

immunosuppressive
yellow fever
vaccination
University of Minnesota
 (9.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Endocrine therapy is the initial treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancers. This study will evaluate the use of venetoclax in combination with capecitabine in adult participants with HR+, HER2-, metastatic breast cancer (MBC) who had disease progression following treatment …

primary tumor
capecitabine tablets
erbb2
HER2
metastatic breast cancer
Masonic Cancer Center /ID# 216101
 (9.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +15 other locations
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

The objectives of this study are to evaluate the safety and efficacy of Zimura intravitreal administration in patients with geographic atrophy secondary to age-related macular degeneration (AMD)

age-related macular degeneration
atrophy
complement c5
maculopathy
geographic atrophy
Retina Center
 (8.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +22 other locations